Instead of the nanostructure and biological activity, this perspective highlights the metabolic processes from biotransformation to bioavailability, to bridge the gap between the cradle (structure design) and endpoint (efficacy and/or safety) of nanomedicines.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: